RELWENDE JUSTİN OUEDRAOGO, NADEEM AHMAD, LASSİNA OUATTARA, ZAHEER UL HAQ, GEORGES ANİCET OUEDRAOGO
Acta Pharmaceutica Sciencia - 2025;63(1):17-43
Mitragyna inermis is a wild plant whose parts are traditionally used. However, there is no particular report on the compounds bioactivity evidence against metabolic disorders. We carried out a literature review of this plant uses and compounds mostly isolated in diabetic and hypertensive states. Following the review, we carried out an in silico study on major targets for research into antidiabetic and antihypertensive candidates. From this study, it emerged that the plant is used in the treatment of diabetes and hypertension. The main compounds isolated from this plant were terpenoids and alkaloids. The in silico study revealed that these compounds could inhibit α-amylase, α-glucosidase and sodium glucose co-transporter 2 in diabetic status, as well as angiotensin converting enzyme in hypertensive status. Most of these compounds could be absorbed and metabolized on the basis of ADME (Adsorption, Distribution, Metabolism and Excretion) pharmacokinetic prediction. Further studies are needed to optimize its activities and conduct in vitro trials.